HOME >> BIOLOGY >> NEWS
UT Southwestern scientist receives international award for lipid research

DALLAS Dr. David J. Mangelsdorf, professor of pharmacology and biochemistry at UT Southwestern Medical Center at Dallas and an associate investigator in the university's Howard Hughes Medical Institute, has been awarded Germany's highly respected Heinrich Wieland Prize for his research on lipids.

The prestigious international science award is given annually to one individual for research in the fields of biochemistry, chemistry and physiology of fats and lipids and its clinical importance.

Dr. Mangelsdorf's research focuses on the mechanisms of nuclear receptor proteins that serve as sensors in protecting human cells against unusually high and possibly toxic levels of lipids, such as cholesterol and fatty acids. These lipid-sensing proteins play a central role in the maintenance of physiological levels of lipids consumed with food. Dr. Mangelsdorf's work signifies an important contribution to the elucidation of the mechanism that the body uses to restore the balance following an increase in cholesterol levels.

Three other UT Southwestern scientists have received the Wieland Prize since its inception in 1963.

Nobel laureates Drs. Michael Brown and Joseph Goldstein claimed the award in 1974 for their research in lipoprotein receptors and the genetic control of cholesterol metabolism. They shared the Nobel Prize in physiology or medicine in 1985 for their discovery of the underlying mechanisms of cholesterol metabolism, which led to the development of statin drugs now used by 13 million Americans to treat high cholesterol.

Dr. John Dietschy, professor of internal medicine, received the Wieland Prize in 1983 while he was chief of gastroenterology at UT Southwestern for his research into the regulation of cholesterol balance in tissues.

"It is quite an honor to be considered in the running for this award, next to these other great names, and even more to receive it," said Dr. Mangelsdorf. "It reflects the great stature o
'"/>

Contact: Donna Steph Hansard
donna.hansard@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
6-Nov-2003


Page: 1 2 3

Related biology news :

1. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. RSV can increase the risk of asthma, UT Southwestern researchers find
4. Searle Scholars program awards $240,000 to UT Southwestern researcher
5. Two molecules work together to aid transport of immune cells, UT Southwestern researchers find
6. Biochemist becomes 15th UT Southwestern faculty member serving on National Academy of Sciences
7. UT Southwestern researchers reveal mechanisms of smooth-muscle contraction
8. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
9. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
10. UT Southwestern researchers discover link that could aid in treatment of kidney cyst diseases
11. UT Southwestern research halts narcolepsy symptoms

Post Your Comments:
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: